国产替罗非班在大量血栓负荷的急性ST段抬高心肌梗死直接介入治疗中的应用

目的对大量血栓负荷的急性ST段抬高心肌梗死患者,急诊直接经皮冠状动脉介入治疗(PCI)中应用国产替罗非班,评价其对冠状动脉血流的影响。方法98例大量血栓负荷的急性ST段抬高心肌梗死大行急诊PCI的患者纳入试验,随机分为替罗非班组52例,对照组46例,比较两组间的冠状动脉血流、ST段回落、住院临床事件等。结果两组术后TIMIⅢ级获得率无统计学差异,替罗非班组的校正TIMI计帧数低于对照组(31.2±3.6)帧vs.(23.6±9.1)帧,P<0.05],术后90min心电图相应导联ST段回落幅度大于对照组(38.9±12.6)%vs.(61.2±13.1)%,P<0.05],住院期间心血管事件发生率、出血发生率两组间无统计学差异。结论急诊PCI术期间短程应用替罗非班能安全、有效地改善冠状动脉血流和心肌灌注。

Application of China-made tirofiban in the treatment of acute ST elevation myocardial infarction with large thrombus burden during primary percutaneous coronary intervention

Objective To investigate the application of China-made tirofiban in the treatment of acute ST elevation myocardial infarction (STEMI) with large thrombus burden during primary percutaneous coronary intervention (PCI). Methods Ninety eight STEMI patients with large thrombus burden detected by emergent coronary angiography were divided into two groups: tirofiban group (52 cases) and control group (46 cases). Coronary flow, ST segment resolution magnitude,clinical events were recorded. Results There was no difference in the achievement of TIMI 3 flow between two groups. Corrected TIMI frame count (CFTC)was lower ((31.2±3.6)fram vs.(23.6±9.1)fram vs. (61.2±13.1) %, P<0.05 ] and ST segment resolution magnitude was higher in the tirofiban group (38.9±12.6 )% vs.(61.2±13.1)%, P<0.05 ] than in the control group. There was no difference in the rate of hemorrhage and cardiovascular events in hospital between two groups. Conclusions Using of tirofiban within short periods can safely improve coronary flow and myocardial perfusion during PCI.